We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Investors' focus is likely to be on GILD???s HIV franchise performance and oncology sales when the company reports ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.21% of ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) is scheduled to release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Gilead Sciences to post earnings of $1.66 ...

Creative Financial Designs Inc. ADV boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 7.4% during the third quarter, HoldingsChannel.com reports. The institutional investor ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...

The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

A former Gilead Sciences Inc. COO says in new court papers that a lawsuit filed against him by a former aide should be transferred to Ventura County, saying he had no personal or business ties to Los ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

The HIV Community Scholars, supported by Gilead Sciences, are invited to attend APCS 2024 to present their innovative ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at ...